
    
      Adults age 18 to < 65 years will be randomly assigned to receive either Fluzone Quadrivalent
      or Fluzone Intradermal Quadrivalent vaccine and adults age â‰¥ 65 years will be randomly
      assigned to receive either Fluzone Quadrivalent or Fluzone High-Dose vaccine. All subjects
      will receive a single dose of their randomly assigned vaccine.

      They will be followed from Visit 1 to Visit 2 for evaluation of safety outcomes. Solicited
      adverse reactions will be collected for 7 days after vaccination. Unsolicited non-serious
      adverse events (AEs) and serious adverse events (SAEs) will be collected from Visit 1 to
      Visit 2.
    
  